Free Trial
OTCMKTS:CLPBY

Coloplast A/S Q3 2026 Earnings Results & Report

Coloplast A/S logo
$7.04 +0.16 (+2.33%)
As of 03:57 PM Eastern

Coloplast A/S met analyst earnings expectations and beat on revenue in its Q3 2026 results, released August 18, 2026. The company reported EPS of $0.10 versus the $0.10 consensus estimate, while revenue of $1.14 billion topped the $1.11 billion estimate by $25.94 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Coloplast A/S EPS Results

Actual EPS
$0.10
Consensus EPS
$0.10
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Coloplast A/S Revenue Results

Actual Revenue
$1.14 billion
Expected Revenue
$1.11 billion
Beat/Miss
Beat by +$25.94 million
YoY Revenue Growth
N/A

Upcoming Earnings

Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Coloplast A/S Q3 2026 Earnings FAQ

Coloplast A/S (OTCMKTS:CLPBY) reported earnings of $0.10 per share for Q3 2026, matching the consensus estimate of $0.10. The report was announced on Tuesday, August 18, 2026.

Coloplast A/S reported revenue of $1.14 billion for Q3 2026, against a consensus estimate of $1.11 billion.

Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Coloplast A/S on the company's earnings history page.

Coloplast A/S Earnings Headlines

Coloplast A/S (OTCMKTS:CLPBY) Stock Price Up 3.9% - Should You Buy?
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
CLPBY Share News Today
Coloplast: Went 'BUY' A Bit Early
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) is a Denmark-based medical technology company that develops and markets products and services for people with intimate and chronic healthcare needs. Its principal business areas include ostomy care, continence care, wound and skin care, and interventional urology.

The company’s product portfolio includes ostomy bags and accessories, skin-protection products, intermittent catheters, bowel-management systems, and devices used in urological procedures. Recognized brands include SenSura and Brava in ostomy care, SpeediCath in continence care, and Peristeen for bowel management.

Coloplast traces its origins to the 1950s, when nurse Elise Sørensen developed an adhesive ostomy bag to help her sister manage an ileostomy. The company was established in 1957 by Aage Louis-Hansen and his wife, Johanne Louis-Hansen. Headquartered in Humlebæk, Denmark, Coloplast serves healthcare professionals and patients in markets across Europe, North America, and other international regions. Kristian Villumsen has served as the company’s president and chief executive officer.

View Coloplast A/S Profile